The future of children and young people’s cancer research

Earlier this year, CCLG launched its new research strategy. Ashley Ball-Gamble, CEO of CCLG, explains what this means for children and young people’s cancer.

When CCLG (then known as the UK Childhood Cancer Studies Group) was founded back in 1977, the goal of its members was simple: to make things better for children with cancer. At the time, fewer than three in 10 children survived their diagnosis, and there was very little research happening in childhood cancer. So, a group of professionals came together to launch clinical trials, collect vital data, and create a supportive community to drive change.

Fast forward to today, and thanks to decades of research around the world, more than 80% of children now survive cancer. But there's much more still to be done – I want everyone to not only survive but thrive after their cancer. Children and young people deserve a life free from the long-term effects of treatment that are still all too common. That’s why funding research is so important to us.

Earlier this year, we changed our name to CCLG: The Children & Young People’s Cancer Association. It’s a name that better reflects our commitment to teenagers and young adults as well as younger children. That change gave us the chance to pause and reflect on what really matters to us as a charity – which led to our innovative new research strategy.

Our new research strategy

We know that making meaningful progress in children and young people’s cancer research isn’t only about handing out grants. So, this strategy isn’t just about what we fund – it’s about how we support the whole research community to work better together, listen more closely to lived experience, and drive lasting change. We have focused on developing four key areas to ensure everything we do contributes to a brighter future for children and young people with cancer...

1. A coordinated, collaborative approach to children and young people’s cancer research

We believe no single charity, hospital or research institute has all the answers. By leading coordination efforts and working together, we’ll ensure that the right research priorities are identified, the highest quality research is funded, and no resources are wasted.

2. Funding the best research, led by the best minds

We’re committed to funding research that drives meaningful progress in the treatment, care, experience and outcomes for children and young people with cancer. By focusing on the areas where we can have the biggest impact, we’ll ensure every pound we spend works harder for our community.

3. Lived experience is at the heart of children and young people’s cancer research

The voices of those with lived experience (those who have had cancer as a child or young person, and their families) are essential to driving children and young people’s cancer research that truly makes a difference. By placing lived experience at the heart of everything we do, we ensure our research addresses real-world priorities, delivers meaningful outcomes, and empowers researchers and families.

4. A thriving children and young people’s cancer research community

Research is a continuous, long-term process, where incremental advancements over time lead to transformative outcomes. To sustain this, we need a research community that attracts talent, nurtures growth, provides opportunities for a wide range of people to get involved, and ensures researchers can thrive.

How this all will help

With CCLG acting not just as a funder of research, but building collaborations and championing this field, we aim to drive bigger, bolder and faster change. That means helping researchers develop their ideas, giving them the support they need to grow, and making sure research is more joined-up, inclusive and impactful than ever before.

We want a future where every one of the top research priorities – identified by patients, families and professionals through the James Lind Alliance – has been addressed. Where every child or young person not only receives the best treatment, but also has a better experience of care. This strategy is a step towards that future.

Find out more 

From Contact magazine issue 108 | Autumn 2025

Related articles from this issue

Why does neurodegeneration occur in Langerhans cell histiocytosis?

A small number of patients with Langerhans cell histiocytosis (LCH) may develop a difficult-to-treat condition called neurodegeneration, where their nerve cells slowly stop working and die. It typically affects the brain causing clumsy movements, unsteadiness and slurred speech.

60 seconds with Prof Bob Phillips

Professor Bob Phillips is the Candlelighters Chair of Supportive Care Research for Children and Young People with Cancer, University of York, Consultant Paediatric Oncologist at Leeds Children’s Hospital and CCLG member.

Ask the expert: Jennifer Laidler

Jennifer Laidler, from the University of Birmingham’s Cancer Research UK Clinical Trials Unit, talks about what clinical trials are and why they are important.

Subscribe to our free quarterly magazine for families of children and young people with cancer

Subscribe to receive our latest quarterly Contact Magazine.